Lenz Therapeutics Inc (LENZ)

Nov 12, 2024, 8:00 AM EST - 2 months ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2024, 11:43 AM EST - 2 months ago

LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 1:51 PM EDT - 2 months ago

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

Oct 27, 2024, 9:00 PM EDT - 2 months ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Oct 21, 2024, 8:00 AM EDT - 3 months ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Oct 15, 2024, 8:00 AM EDT - 3 months ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

ABOS

Aug 30, 2024, 8:00 AM EDT - 5 months ago

LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks

Aug 16, 2024, 7:43 PM EDT - 5 months ago

LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 5 months ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 5 months ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

Aug 7, 2024, 4:01 PM EDT - 5 months ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 10, 2024, 8:00 AM EDT - 7 months ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

May 30, 2024, 8:00 AM EDT - 8 months ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

May 11, 2024, 7:26 AM EDT - 8 months ago

LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 9 months ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 1, 2024, 4:01 PM EDT - 9 months ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Apr 3, 2024, 7:49 AM EDT - 10 months ago

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

Apr 3, 2024, 7:00 AM EDT - 10 months ago

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

Apr 2, 2024, 4:01 PM EDT - 10 months ago

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Mar 21, 2024, 4:30 PM EDT - 10 months ago

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress